Significant Reduction in ST-Elevation MI With Icosapent Ethyl in REDUCE-IT - 28/07/24

Doi : 10.1016/j.hlc.2024.06.533

J. Amerena ¹, P. Steg ², D. Bhatt ³, G. Watts ⁴, R. Giugliano ⁵, M. Miller ⁶, E. Brinton ⁷, T. Jacobson ⁸, S. Ketchum ⁹, G. Giugliano ¹⁰, R. Mason ¹¹, J. Tardif ¹², F. Martens ¹³, C. Ballantyne ¹⁴, M. Budoff ¹⁵, C. Gibson ¹⁶
¹ University Hospital Geelong, Geelong, Vic, Australia
² Université de Paris, FACT (French Alliance for Cardiovascular Trials), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris, France
³ Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
⁴ School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
⁵ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
⁶ Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
⁷ Utah Lipid Center, Salt Lake City, UT, USA
⁸ Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
⁹ Amarin Pharma, Inc., Bridgewater, NJ, USA
¹⁰ Children’s National Hospital, Washington DC, USA
¹¹ Brigham and Women’s Hospital, Harvard Medical School, and Elucida Research, Boston, MA, USA
¹² Montreal Heart Institute, Université de Montréal, Montreal, Canada
¹³ Dutch Network for Cardiovascular Research and the Department of Cardiology, Deventer Hospital, Deventer, The Netherlands
¹⁴ Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA
¹⁵ David Geffen School of Medicine, Lundquist Institute, Torrance, CA, USA
¹⁶ Harvard Medical School, Baim Institute for Clinical Research, Boston, MA, USA

El texto completo de este artículo está disponible en PDF.